Related Experiment Video
Updated: Jan 17, 2026
Detection of Functional Matrix Metalloproteinases by Zymography
Published on: November 8, 2010
Matrix metalloproteinases are hallmark early biomarkers and therapeutic targets in FSHD
Abstract:
Matrix remodeling by metalloproteinases (MMPs) is essential for maintaining muscle homeostasis; however, their dysregulation can drive degenerative processes. By interrogating biopsy RNA-Seq data, we showed that MMP expression correlated with disease severity in facioscapulohumeral muscular dystrophy (FSHD). In the iDUX4pA FSHD mouse model, MMP levels also progressively increased in response to double homeobox 4-induced (DUX4-induced) muscle degeneration. Single-cell RNA-Seq further identified fibroadipogenic progenitors (FAPs) and macrophages as the primary sources of MMPs, particularly MMP2, MMP14, and MMP19, in dystrophic muscle. Treatment with the pan-MMP inhibitor batimastat alleviated inflammation and fibrosis, improved muscle structure, and decreased the number of FAPs and infiltrating macrophages. These findings underscore the role of MMPs in driving muscle degeneration in FSHD, highlight MMPs as functional biomarkers of disease, and support MMP inhibitors as a DUX4-independent therapeutic approach to limit fibroadipogenesis and promote muscle regeneration.
Insights
Matrix metalloproteinases (MMPs) drive muscle degeneration in facioscapulohumeral muscular dystrophy (FSHD). Inhibiting MMPs reduced fibrosis and inflammation, suggesting MMP inhibitors as a potential therapy for FSHD.
Area of Science:
- Muscle Biology
- Molecular Medicine
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) are crucial for muscle homeostasis, but their dysregulation contributes to degenerative diseases.
- Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive muscle degeneration, with the role of MMPs not fully elucidated.
Purpose of the Study:
- To investigate the role of MMPs in FSHD pathogenesis.
- To identify the cellular sources of MMPs in dystrophic muscle.
- To evaluate the therapeutic potential of MMP inhibition in FSHD.
Main Methods:
- Analysis of RNA-Seq data from FSHD patient biopsies and an iDUX4pA FSHD mouse model.
- Single-cell RNA-Seq to identify MMP-producing cells.
- Treatment of the FSHD mouse model with the pan-MMP inhibitor batimastat.
Main Results:
- MMP expression correlated with disease severity in FSHD patients and increased during DUX4-induced degeneration in mice.
- Fibroadipogenic progenitors (FAPs) and macrophages were identified as major MMP sources (MMP2, MMP14, MMP19) in dystrophic muscle.
- Batimastat treatment reduced inflammation, fibrosis, and FAP/macrophage infiltration, while improving muscle structure.
Conclusions:
- MMPs play a significant role in driving muscle degeneration in FSHD.
- MMPs serve as functional biomarkers for FSHD progression.
- MMP inhibitors represent a promising DUX4-independent therapeutic strategy for FSHD, targeting fibroadipogenesis and promoting muscle regeneration.
